For treatment of mild to moderate COVID-19 patients, favipiravir exhibited a clinical resolution rate of >90%.

A multicentric, retrospective, single-arm study was conducted to assess the safety and efficacy of favipiravir (an RNA-dependent RNA polymerase inhibitor) in real-world clinical practice.

Examination of medical records was done to explore favipiravir's therapeutic benefit. A total of 360 people met inclusion criteria and 358 people (average age: 51.80 ± 16.45 years) were available for final analysis. Males made up 58.46% of the trial population.

Myalgia-fatigue, fever, and cough were the most commonly encountered symptoms. The median time to fever relief and clinical cure was 4 and 5 days respectively. Average length of stay in hospital was found to be 6 days.  Side effects were experienced by 8% of subjects. Giddiness, fatigue, headache, decreased appetite, diarrhea, and hepatic enzyme elevation were the commonly noted symptoms.

The antiviral agent favipiravir exhibited a good clinical cure rate, and was well tolerated with few transient adverse events in coronavirus-infected people.